NovoLog Mix 70 / 30

NovoLog Mix 70/30 is a brand name of insulin aspart/insulin aspart protamine, approved by the FDA in the following formulation(s):

NOVOLOG MIX 70/30 (insulin aspart protamine recombinant; insulin aspart recombinant - injectable; subcutaneous)

• 
  Manufacturer: NOVO NORDISK INC
  
  Approval date: November 1, 2001
  
  Strength(s): 70 UNITS/ML;30 UNITS/ML ^[RLD]

Has a generic version of NovoLog Mix 70/30 been approved?

No. There is currently no therapeutically equivalent version of NovoLog Mix 70/30 available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of NovoLog Mix 70/30. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Asp.sup.B28 insulin crystals
  Patent 5,547,930
  Issued: August 20, 1996
  Inventor(s): Balschmidt; Per
  Assignee(s): Novo Nordisk A/S
  The present invention relates to insulin crystals comprising ASP.sup.B28 and protamine, and pharmaceutical preparations containing same. The crystals and preparations exhibit rapid onset and prolonged activity when administered in vivo.
  
  Patent expiration dates:
  
  
  • September 28, 2013
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Insulin analogues
  Patent 5,618,913
  Issued: April 8, 1997
  Inventor(s): Brange; Jens J. V. & Norris; Kjeld & Hansen; Mogens T.
  Assignee(s): Novo Nordisk A/S
  Novel rapid-acting human insulin analogues are provided having less tendency to self-association into dimers, tetramers, hexamers, or polymers. The novel human insulin analogues are formed by substituting one or more of the amino acid residues of human insulin with naturally occuring amino acid residues. The amino acid residue substitutions are preferably more hydrophilic than the natural amino acid residue at the respective position in the molecule. Furthermore, the insulin analogues have the same charge or a greater negative charge at neutral pH than that of human insulin. Preferred amino acid substitutions are Asp, Glu, Ser, Thr, His, and Ile, and more preferred substitutions are Asp and Glu. The novel insulin analogues can be used for the preparation of rapid-acting insulin solutions.
  
  Patent expiration dates:
  
  
  • June 7, 2014
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • December 7, 2014
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Asp.sup.B28 insulin compositions
  Patent 5,834,422
  Issued: November 10, 1998
  Inventor(s): Balschmidt; Per
  Assignee(s): Novo Nordisk A/S
  The present invention relates to insulin crystals comprising ASP.sup.B28 and protamine, and pharmaceutical preparations containing same, The crystals and preparations exhibit rapid onset and prolonged activity when administered in vivo.
  
  Patent expiration dates:
  
  
  • September 28, 2013
    
    ✓ 
    Patent use: METHOD OF TREATING A PATIENT SUFFERING FROM DIABETES MELLITUS
    ✓ 
    Drug product
  
  



• 
  ASP.sup.B28 insulin crystals
  Patent 5,840,680
  Issued: November 24, 1998
  Inventor(s): Balschmidt; Per
  Assignee(s): Novo Nordisk A/S
  The present invention relates to insulin crystals comprising ASP.sup.B28 and protamine, and pharmaceutical preparations containing same. The crystals and preparations exhibit rapid onset and prolonged activity when administered in vivo.
  
  Patent expiration dates:
  
  
  • September 28, 2013
    
    ✓ 
    Patent use: METHOD OF TREATING A PATIENT SUFFERING FROM DIABETES MELLITUS
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Insulin preparations containing NaCl
  Patent 5,866,538
  Issued: February 2, 1999
  Inventor(s): Norup; Elsebeth & Langkj.ae butted.r; Liselotte & Havelund; Svend
  Assignee(s): Novo Nordisk A/S
  Insulin preparations of superior chemical stability, comprising human insulin or an analogue or derivative thereof, glycerol and/or mannitol, and 5 to 100 mM of a halogenide are disclosed.
  
  Patent expiration dates:
  
  
  • June 19, 2017
    
    ✓ 
    Drug product
  
  

See also...

• NovoLog Mix 70/30 Cartridges Consumer Information (Wolters Kluwer)
• NovoLog Mix 70/30 Vials Consumer Information (Wolters Kluwer)
• NovoLog Mix 70/30 Consumer Information (Cerner Multum)
• Novolog Mix 70/30 Advanced Consumer Information (Micromedex)
• Insulin Aspart Protamine/Insulin Aspart Cartridges Consumer Information (Wolters Kluwer)
• Insulin Aspart Protamine/Insulin Aspart Vials Consumer Information (Wolters Kluwer)
• Insulin aspart and insulin aspart protamine Consumer Information (Cerner Multum)
• Insulin aspart protamine and insulin aspart Subcutaneous Advanced Consumer Information (Micromedex)